Blackstone Leads $200 Million Round in DNANexus

<p class&equals;"is-style-body-2"><strong>MOUNTAIN VIEW<&sol;strong><strong> —<&sol;strong><a href&equals;"https&colon;&sol;&sol;www&period;dnanexus&period;com&sol;"><strong> <&sol;strong><&sol;a><a href&equals;"https&colon;&sol;&sol;www&period;dnanexus&period;com&sol;">DNAnexus&comma; Inc&period;<&sol;a>&comma; a leading provider of cloud-based biomedical data analysis software serving the life sciences community&comma; has secured a &dollar;200 million financing round to accelerate the global adoption of its technology&comma; translating the world’s complex multi-omics and clinical data into tangible insights and personalized treatments&period; The round was led by funds managed by Blackstone Growth &lpar;BXG&rpar;&comma; with participation from existing investors Northpond Ventures&comma; GV&comma; Perceptive Advisors&comma; Innovatus Capital Partners&comma; and Foresite Capital&period;<&sol;p>&NewLine;<p>DNAnexus will use the funding to advance its core genomics and multi-omics platform&comma; continue its international growth&comma; and support the integration of new AI and machine learning technologies and tools&period; The company is focused on allowing more customers to rapidly analyze complex genomic&comma; transcriptomic&comma; proteomic&comma; metabolomic&comma; and clinical datasets together on a single&comma; secure&comma; and scalable platform to help reveal insights that can accelerate precision medicine&period;&plus;<&sol;p>&NewLine;<p class&equals;"is-style-body-2">Geneticists predict that by 2025 more than 500 million genomes will have been sequenced&comma; generating 40 exabytes of data&period; Only a fraction of this data is currently being utilized for drug discovery&period; Investment in genomics programs has been growing rapidly in pharmaceutical and clinical diagnostic companies driven by an increasing focus on new&comma; innovative drugs and diagnostic tests&period; DNAnexus provides the technology and products to support this rapidly growing ecosystem and drive critical insights from massive genomic&comma; multi-omic&comma; and clinical datasets&period;<&sol;p>&NewLine;<p class&equals;"is-style-body-2">DNAnexus has more than 12&comma;000 platform users across 48 countries&comma; and counts seven of the top 10 pharmaceutical and eight of the top 10 diagnostics companies as customers&period; The platform now stores more than 65 petabytes of data&comma; a number that has grown 70&percnt; per year since 2015&period; The company built and continues to support the <a href&equals;"https&colon;&sol;&sol;www&period;dnanexus&period;com&sol;partnerships&sol;ukbiobank">UK Biobank’s Research Analysis Platform<&sol;a>&comma; allowing approved researchers global access to the world’s largest&comma; most comprehensive biomedical database and tools&period; DNAnexus also exclusively partnered with the FDA to power <a href&equals;"https&colon;&sol;&sol;precision&period;fda&period;gov&sol;">precisionFDA<&sol;a>&comma; a secure&comma; cloud-based&comma; high-performance platform enabling access by FDA researchers and reviewers&comma; as well as sponsors from the private sector&comma; to use the data and tools in a collaborative environment&comma; furthering the standards by which multi-omic data is included in FDA submissions&period;<&sol;p>&NewLine;<p class&equals;"is-style-body-2">&OpenCurlyDoubleQuote;The funding enables us to accelerate our product roadmap to meet the global demand for technologies harnessing the power of biomedical data and driving precision medicine forward&comma;” said Richard Daly&comma; Chief Executive Officer at DNAnexus&period; &OpenCurlyDoubleQuote;Blackstone has shown a deep commitment to the healthcare&comma; life sciences&comma; and technology industries with a global network and operating resources&period; Blackstone will be a strong partner as we grow our business and support the new wave of biomedical insights generated by our customers using large-scale clinical&comma; multi-omics data&period;”<&sol;p>&NewLine;<p class&equals;"is-style-body-2">Ram Jagannath&comma; Global Head of Healthcare for Blackstone&comma; said&colon; &OpenCurlyDoubleQuote;We have seen a rapid proliferation of healthcare data over the last several years&comma; driven by the advent of new technologies and the surging availability of diagnostic tests&period; The DNAnexus Platform enables the life sciences industry to derive critical insights from multi-omic&comma; clinical&comma; and phenotypic data to hasten the development and delivery of novel therapeutics&comma; getting them into the hands of patients who need them more quickly and cost-effectively&period; We’re proud to support the next phase of growth for the company as it continues executing on its mission to improve human healthcare&period;”<&sol;p>&NewLine;<p class&equals;"is-style-body-2">Blackstone Growth’s investment in DNAnexus follows the broader firm’s recent investments in life sciences and pharma IT&comma; including Medable&comma; Precision Medicine Group&comma; Cryoport&comma; and Life Sciences Logistics&period; Additionally&comma; in 2018&comma; the firm established Blackstone Life Sciences&comma; a private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors&period; The Blackstone Life Sciences team has deep investing and operating expertise in product development and commercialization&comma; and strong relationships with leading pharmaceutical and medical technology companies including AstraZeneca&comma; Novartis&comma; and Pfizer&period;<&sol;p>&NewLine;